|
Platelet function inhibitors
Citations 181-190 of 249 total displayed.
|
Past content
(since Oct 2000):
|
- Clinical Investigations and Reports
Atorvastatin Reduces the Ability of Clopidogrel to Inhibit Platelet Aggregation: A New Drug–Drug Interaction
- Wei C. Lau, Lucy A. Waskell, Paul B. Watkins, Charlene J. Neer, Kevin Horowitz, Amy S. Hopp, Alan R. Tait, David G.M. Carville, Kirk E. Guyer, and Eric R. Bates
Circulation published November 25, 2002, doi:10.1161/01.CIR.0000047060.60595.CC
[Abstract]
[Full text]
- Articles
Lack of Benefit From Intravenous Platelet Glycoprotein IIb/IIIa Receptor Inhibition as Adjunctive Treatment for Percutaneous Interventions of Aortocoronary Bypass Grafts. A Pooled Analysis of Five Randomized Clinical Trials
- Marco Roffi, Debabrata Mukherjee, Derek P. Chew, Deepak L. Bhatt, Leslie Cho, Mark A. Robbins, Khaled M. Ziada, Danielle M. Brennan, Stephen G. Ellis, and Eric J. Topol
Circulation published November 18, 2002, doi:10.1161/01.CIR.0000041250.89627.A9
[Abstract]
- Cardiology Patient Pages
Treatment of Blood Clots
- Samuel Z. Goldhaber and Nicole Grasso-Correnti
Circulation 2002;106:e138-140e, doi:10.1161/01.CIR.0000038923.61628.3D
[Full text]
- Correspondence
Every Acronym Should Be Defined When It First Appears in a Publication
- Tsung O. Cheng
Circulation 2002;106:e134, doi:10.1161/01.CIR.0000036542.05270.A9
[Full text]
- Current Perspectives
Clinical Implications of Percutaneous Coronary Intervention-Clopidogrel in Unstable angina to prevent Recurrent Events (PCI-CURE) Study: A US Perspective
- Peter B. Berger and Steven Steinhubl
Circulation 2002;106:2284-2287, doi:10.1161/01.CIR.0000035924.70846.20
[Full text]
- Editorials
Acute Pulmonary Embolism: Don’t Ignore the Platelet
- Piotr Sobieszczyk, Michael C. Fishbein, and Samuel Z. Goldhaber
Circulation 2002;106:1748-1749, doi:10.1161/01.CIR.0000035277.48823.01
[Full text]
- Correspondence
Effect of Abciximab on Prothrombin Activation and Thrombin Generation in Acute Coronary Syndromes Without ST-Segment Elevation
- Koon-Hou Mak
Circulation 2002;106:e57, doi:10.1161/01.CIR.0000031832.54054.A1
[Full text]
- Editorials
Evidence-Based Risk Stratification to Target Therapies in Acute Coronary Syndromes
- Christopher P. Cannon
Circulation 2002;106:1588-1591, doi:10.1161/01.CIR.0000030416.80014.F4
[Full text]
- Clinical Investigations and Reports
Randomized COMparison of Platelet Inhibition With Abciximab, TiRofiban and Eptifibatide During Percutaneous Coronary Intervention in Acute Coronary Syndromes: The COMPARE Trial
- Wayne B. Batchelor, Thaddeus R. Tolleson, Yao Huang, Rhonda L. Larsen, R. Michael Mantell, Patricia Dillard, Marie Davidian, Daowen Zhang, Warren J. Cantor, Michael H. Sketch, Jr, E. Magnus Ohman, James P. Zidar, Daniel Gretler, Peter M. DiBattiste, James E. Tcheng, Robert M. Califf, and Robert A. Harrington
Circulation 2002;106:1470-1476; published online before print as doi:10.1161/01.CIR.0000029744.01096.1F
[Abstract]
[Full text]
- Articles
Randomized COMparison of Platelet Inhibition With Abciximab, TiRofiban and Eptifibatide During Percutaneous Coronary Intervention in Acute Coronary Syndromes. The COMPARE Trial
- Wayne B. Batchelor, Thaddeus R. Tolleson, Yao Huang, Rhonda L. Larsen, R. Michael Mantell, Patricia Dillard, Marie Davidian, Daowen Zhang, Warren J. Cantor, Michael H. Sketch, Jr, E. Magnus Ohman, James P. Zidar, Daniel Gretler, Peter M. DiBattiste, James E. Tcheng, Robert M. Califf, and Robert A. Harrington
Circulation published September 3, 2002, doi:10.1161/01.CIR.0000029744.01096.1F
[Abstract]
|
|
